Evidence map›Paper›PMID 39423230›Full record

ArticlePLoS pathogens2024

Resistance to Cry14A family Bacillus thuringiensis crystal proteins in Caenornabditis elegans operates via the nhr-31 transcription factor and vacuolar-type ATPase pathway.

Youmie Kim, Thanh-Thanh Nguyen, Daniel J Durning, Takao Ishidate, Ozkan Aydemir, Craig C Mello, Yan Hu, Theodore W Kahn, Raffi V Aroian

Abstract read
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Youmie KimProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America.
Thanh-Thanh NguyenProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America.
Daniel J DurningRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America.
Takao IshidateRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America.
Ozkan AydemirProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America.
Craig C MelloRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America.
Yan HuProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America.
Theodore W KahnBASF Corporation, Research Triangle Park, North Carolina, United States of America.
Raffi V AroianProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America.ORCID 0000-0002-9741-3834

Funding

Function/optimization of a nematicidal Cry toxin arsenalR01AI056189 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAFFI V AROIAN · 2005 to 2026
$11.0M
NIAID NIH HHS R01 AI056189
6 · The paper itself

Abstract

Bacillus thuringiensis (Bt) has been successfully used commercially for more than 60 years for biocontrol of insect pests. Since 1996, transgenic plants expressing Bt crystal (Cry) proteins have been used commercially to provide protection against insects that predate on corn and cotton. More recently, Bt Cry proteins that target nematodes have been discovered. One of these, Cry14Ab, has been expressed in transgenic soybean plants and found to provide significant protection against the soybean cyst nematode, Heterodera glycines. However, to date there has been no description of high-level resistance to any Cry14A family protein in nematodes. Here, we describe forward genetic screens to identify such mutants using the nematode Caenorhabditis elegans. Although non-conditional screens failed to identify highly resistant C. elegans, a conditional (temperature-sensitive) genetic screen identified one mutant, bre-6(ye123) (for Bt protein resistant), highly resistant to both Cry14Aa and Cry14Ab. The mutant comes at a high fitness cost, showing significant delays in growth and development and reduced fecundity. bre-6(ye123) hermaphrodites are only weakly resistant to copper intoxication, indicating that the mutant is not highly resistant to all insults. Backcrossing-whole genome sequencing was used to identify the gene mutated in ye123 as the nuclear hormone receptor nhr-31. RNAi, DNA rescue, and CRISPR analyses confirm that resistance to Cry14Aa intoxication in bre-6(ye123) is due to mutation of nhr-31 and was renamed nhr-31(ye123). As predicted for a mutation in this gene, nhr-31(ye123) animals showed significantly reduced expression of most of the subunits of the C. elegans vacuolar ATPase (vATPase). Mutants in the vATPase subunits unc-32 and vha-7 also show resistance to Cry14Aa and/or Cry14Ab. These data demonstrate that nhr-31 and the vATPase play a significant role in the intoxication of C. elegans by Cry14A family proteins, that reduction in vATPase levels result in high resistance to Cry14A family proteins, and that such resistance comes at a high fitness cost. Based on the relative difficulty of finding resistant mutants and the fitness cost associated with the vATPase pathway, our data suggest that transgenic Cry14Ab plants may hold up well to resistance by nematode parasites.

Indexed as

Bacillus thuringiensisBacillus thuringiensis ToxinsBacterial ProteinsCaenorhabditis elegansCaenorhabditis elegans ProteinsEndotoxinsHemolysin ProteinsAnimalsInsecticide ResistanceTranscription FactorsVacuolar Proton-Translocating ATPasesBacillus thuringiensis ToxinsBacterial ProteinsCaenorhabditis elegans ProteinsEndotoxinsHemolysin Proteinsinsecticidal crystal protein, Bacillus ThuringiensisTranscription FactorsVacuolar Proton-Translocating ATPases

Identifiers

PMID39423230
PMCPMC11524453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.